Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the managEment of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms FOREFRONT
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 20 Apr 2018 Status changed from active, no longer recruiting to completed.
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.